• ITM’s expansive pipeline and clinical strategy will be enhanced by Dr. Celine Wilke’s extensive background in radiopharmaceutical drug development, regulatory affairs, and clinical strategies.

Garching / Munich, Germany, April 01, 2025 – ITM, a prominent radiopharmaceutical biotech firm, has announced the appointment of Dr. Celine Wilke as Chief Medical Officer. Dr. Wilke brings nearly two decades of industry experience to the role, primarily in radiopharmaceutical drug development. Previously, as Senior Global Program Clinical Head for prostate cancer at Novartis, Dr. Wilke managed clinical trials for radiopharmaceutical therapies and imaging agents, leading to the global approvals of Pluvicto® and Locametz®. At ITM, she will spearhead the clinical development and medical teams, guiding ITM-11 toward potential market approval and accelerating the advancement of the company’s radiopharmaceutical pipeline.

Dr. Andrew Cavey, Chief Executive Officer of ITM, stated, “Celine’s extensive experience in advancing radiopharmaceutical precision oncology treatments, from early development to regulatory approval, is invaluable. Her leadership of our medical team will be crucial in progressing our pipeline and providing new treatment options for patients. I also extend my sincere gratitude to Dr. Heike Oberwittler for her leadership as Interim Chief Medical Officer. We appreciate her significant contributions and anticipate her continued leadership in advancing our clinical development efforts.”

Dr. Wilke joins ITM from Novartis/Basel, where she held various senior leadership positions focused on strategic drug development, including regulatory discussions, global NDA submissions, and functional processes. Prior to her role as Senior Global Program Clinical Head for prostate cancer, she was Global Program Clinical Head for Myeloproliferative Neoplasms (MPN) and Graft-versus-Host Disease (GvHD), where she oversaw the global medical development for Jakavi® in acute and chronic GvHD up to NDA submission and approval. She also directed several pivotal clinical trials for novel compounds. As Senior Clinical Development Medical Director for breast cancer, she played a central role in the pivotal Phase 3 SOLAR-1 trial, securing worldwide approvals of PIQRAY® and two companion diagnostics, and participated in related launch activities. Before Novartis, Dr. Wilke was Head of Clinical Drug Development and Regulatory Affairs at MediGene. Dr. Wilke is a board-certified physician specializing in clinical pharmacology and oncology. She received her medical training at the Medical School University Rostock, Germany, University Bari, Italy, and California State University, Fullerton.

Dr. Celine Wilke, Chief Medical Officer of ITM, commented, “Radiopharmaceuticals are transforming cancer care by providing highly targeted treatments with precision and efficacy across a wide range of solid tumors. ITM has been a pioneering force in this field for decades, combining extensive expertise in isotope production with a strong pipeline of innovative therapies. The positive Phase 3 data for ITM-11 underscores the potential of this dynamic drug class. I am eager to collaborate with ITM’s medical team and leadership to advance our portfolio and deliver these targeted treatment options to the patients who need them most.”

About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech company, is committed to delivering next-generation radiopharmaceutical therapeutics and diagnostics for difficult-to-treat tumors. Our goal is to meet the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply. With improved patient outcomes as the core principle, ITM advances a broad precision oncology pipeline, including several Phase 3 studies, combining the company’s high-quality radioisotopes with various targeting molecules. Leveraging our two decades of pioneering radiopharma expertise, central industry position, and established global network, ITM strives to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life.

ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:

Attachments